Réactifs et instruments pour l'immunologie, la biologie cellulaire et la biologie moléculaire.

MG-132 [133407-82-6]

Imprimer

Référence HY-13259-5mg

Conditionnement : 5mg

Marque : MedChemExpress

Demander plus d'informations

Description

MG-132 (Z-Leu-Leu-Leu-al) is a potent proteasome and calpain inhibitor with IC₅₀s of 100 nM and 1.2 μM, respectively. MG-132 effectively blocks the proteolytic activity of the 26S proteasome complex. MG-132, a peptide aldehyde, also is an autophagy activator. MG-132 also induces apoptosis^[1]^[2]^[3].

IC₅₀ & Target

IC50: 100 nM (Proteasome), 1.2 μM (Calpain)^[1]^[3]

Cellular Effect

Cell Line	Type	Value	Description	References
COS-7	IC₅₀	< 10 μM Compound: MG132	Cytotoxicity against african green monkey COS7 cells by XTT method Cytotoxicity against african green monkey COS7 cells by XTT method	[PMID: 18088097]
HCT-116	IC₅₀	0.82 μM Compound: MG132	Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31312413]
HEK293	IC₅₀	0.009 μM Compound: MG132	Inhibition of chymotrypsin-like activity of proteasome beta-5 subunit in HEK293 cells using Suc-LLVY-Glo as substrate incubated for 2 hrs prior to substrate addition measured after 10 mins by cell-based proteasome-Glo beta5 assay Inhibition of chymotrypsin-like activity of proteasome beta-5 subunit in HEK293 cells using Suc-LLVY-Glo as substrate incubated for 2 hrs prior to substrate addition measured after 10 mins by cell-based proteasome-Glo beta5 assay	[PMID: 23540790]
HEK293	IC₅₀	0.6 μM Compound: MG132	Inhibition of postacid activity of 20s proteasome beta-1 subunit in HEK293 cells using Z-nLPnLD-Glo as substrate incubated for 2 hrs prior to substrate addition measured after 10 mins by cell-based proteasome-Glo beta1 assay Inhibition of postacid activity of 20s proteasome beta-1 subunit in HEK293 cells using Z-nLPnLD-Glo as substrate incubated for 2 hrs prior to substrate addition measured after 10 mins by cell-based proteasome-Glo beta1 assay	[PMID: 23540790]
HL-60	IC₅₀	0.068 μM Compound: MG132	Inhibitory concentration to inhibit chymotrypsin-like activity of 20S proteasome prepared from human leukemia HL-60 cells was determined Inhibitory concentration to inhibit chymotrypsin-like activity of 20S proteasome prepared from human leukemia HL-60 cells was determined	[PMID: 15780623]
HL-60	IC₅₀	1.4 μM Compound: MG132	Inhibitory concentration to inhibit the PGPH activity of 20S proteasome prepared from human leukemia HL-60 cells was determined Inhibitory concentration to inhibit the PGPH activity of 20S proteasome prepared from human leukemia HL-60 cells was determined	[PMID: 15780623]
HL-60	IC₅₀	4.5 μM Compound: MG132	Inhibitory concentration to inhibit trypsin-like activity of 20S proteasome from human leukemia HL-60 cells was determined Inhibitory concentration to inhibit trypsin-like activity of 20S proteasome from human leukemia HL-60 cells was determined	[PMID: 15780623]
HUVEC	IC₅₀	0.6 μM Compound: 1, MG-132	Inhibition of TNFalpha stimulated human NF-kappaB-mediated beta lactamase gene expression in HUVEC Inhibition of TNFalpha stimulated human NF-kappaB-mediated beta lactamase gene expression in HUVEC	[PMID: 18024113]
Huh-7	IC₅₀	< 10 μM Compound: MG132	Cytotoxicity against human HuH7 cells by XTT method Cytotoxicity against human HuH7 cells by XTT method	[PMID: 18088097]
MCF-10A	IC₅₀	0.29 μM Compound: MG-132	Growth inhibition of human MCF10A cells after 72 hrs by CellTiter-Blue assay Growth inhibition of human MCF10A cells after 72 hrs by CellTiter-Blue assay	[PMID: 24153206]
MCF7	IC₅₀	0.13 μM Compound: MG-132	Growth inhibition of human MCF7 cells after 72 hrs by CellTiter-Blue assay Growth inhibition of human MCF7 cells after 72 hrs by CellTiter-Blue assay	[PMID: 24153206]
MCF7	IC₅₀	0.3 μM Compound: MG-132	Cytotoxicity against human MCF7 cells Cytotoxicity against human MCF7 cells	[PMID: 18598018]
MDA-MB-231	IC₅₀	0.18 μM Compound: MG-132	Growth inhibition of human MDA-MB-231 cells after 72 hrs by CellTiter-Blue assay Growth inhibition of human MDA-MB-231 cells after 72 hrs by CellTiter-Blue assay	[PMID: 24153206]
MDA-MB-231	IC₅₀	0.25 μM Compound: MG-132	Cytotoxicity against human MDA-MB-231 cells Cytotoxicity against human MDA-MB-231 cells	[PMID: 18598018]
NCI-H23	IC₅₀	0.48 μM Compound: MG-132	Cytotoxicity against human NCI-H23 cells after 72 hrs by CellTiter 96 AQueous one solution cell proliferation assay Cytotoxicity against human NCI-H23 cells after 72 hrs by CellTiter 96 AQueous one solution cell proliferation assay	[PMID: 30964987]
NCI-H727	IC₅₀	0.98 μM Compound: MG-132	Cytotoxicity against human NCI-H727 cells after 72 hrs by CellTiter 96 AQueous one solution cell proliferation assay Cytotoxicity against human NCI-H727 cells after 72 hrs by CellTiter 96 AQueous one solution cell proliferation assay	[PMID: 30964987]
NCI-H929	IC₅₀	0.17 μM Compound: MG-132	Cytotoxicity against human NCI-H929 cells after 3 days by Alamar blue assay Cytotoxicity against human NCI-H929 cells after 3 days by Alamar blue assay	[PMID: 24625088]
OCI-Ly3	IC₅₀	> 10 μM Compound: 1, MG-132	Cytotoxicity against NF-kappaB overexpressing human OCI-Ly3 cells after 4 hrs Cytotoxicity against NF-kappaB overexpressing human OCI-Ly3 cells after 4 hrs	[PMID: 18024113]
PC-3	IC₅₀	600 nM Compound: 5b	Antiproliferative activity against human PC3 cell line Antiproliferative activity against human PC3 cell line	[PMID: 16686537]
RAW264.7	IC₅₀	0.08 μM Compound: MG-132	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-stimulated NO production after 18 hrs by Griess reagent method Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-stimulated NO production after 18 hrs by Griess reagent method	[PMID: 22620677]
RAW264.7	IC₅₀	0.08 μg/mL Compound: MG132	Inhibition of LPS and IFN-gamma-stimulated nitric oxide production in mouse RAW264.7 cells after 18 hrs by Griess method Inhibition of LPS and IFN-gamma-stimulated nitric oxide production in mouse RAW264.7 cells after 18 hrs by Griess method	[PMID: 26351042]
RAW264.7	IC₅₀	0.1 μM Compound: MG-132	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 18 hrs by Griess method Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 18 hrs by Griess method	[PMID: 23819871]
RAW264.7	IC₅₀	0.1 μM Compound: MG-132	Inhibition of LPS-stimulated NO production in mouse RAW264.7 cells after 18 hrs by Griess assay Inhibition of LPS-stimulated NO production in mouse RAW264.7 cells after 18 hrs by Griess assay	[PMID: 24219809]
RAW264.7	IC₅₀	0.1 μM Compound: MG-132	Inhibition of nitric oxide production in LPS-stimulated mouse RAW264.7 cells after 18 hrs by griess reagent based plate reader analysis Inhibition of nitric oxide production in LPS-stimulated mouse RAW264.7 cells after 18 hrs by griess reagent based plate reader analysis	[PMID: 24697496]
RAW264.7	IC₅₀	0.1 μM Compound: MG132	Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells by Griess method Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells by Griess method	[PMID: 24597894]
RAW264.7	IC₅₀	0.1 μM Compound: MG132	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production incubated for 18 hrs by Griess method Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production incubated for 18 hrs by Griess method	[PMID: 33422907]
RAW264.7	IC₅₀	0.15 μM Compound: MG-132	Inhibition of nitric oxide production in LPS-stimulated mouse RAW264.7 cells measured after 18 hrs by Griess reagent based multilabel plate reader analysis Inhibition of nitric oxide production in LPS-stimulated mouse RAW264.7 cells measured after 18 hrs by Griess reagent based multilabel plate reader analysis	[PMID: 23327668]
RAW264.7	IC₅₀	0.15 μM Compound: MG-132	Inhibition of LPS-induced NO production in mouse RAW264.7 cells at 25 uM preincubated with compound followed by LPS challenge measured after 18 hrs by Griess method Inhibition of LPS-induced NO production in mouse RAW264.7 cells at 25 uM preincubated with compound followed by LPS challenge measured after 18 hrs by Griess method	[PMID: 26757019]
RAW264.7	IC₅₀	0.16 μM Compound: MG-132	Anti-inflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-stimulated NO production after 18 hrs by Griess reagent based assay Anti-inflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-stimulated NO production after 18 hrs by Griess reagent based assay	[PMID: 30629435]
RAW264.7	IC₅₀	0.17 μg/mL Compound: MG-132	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of IFNgamma-induced NO production after 5 mins by Greiss method Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of IFNgamma-induced NO production after 5 mins by Greiss method	[PMID: 22277277]
RAW264.7	IC₅₀	0.17 μg/mL Compound: MG-132	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production after 5 mins by Greiss method Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production after 5 mins by Greiss method	[PMID: 22277277]
RAW264.7	IC₅₀	0.18 μM Compound: MG-132	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 18 hrs by Griess assay Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 18 hrs by Griess assay	[PMID: 27203291]
RAW264.7	IC₅₀	0.2 μM Compound: MG-132	Antiinflammatory activity in mouse RAW264.7 cells assessed as reduction in LPS-induced NO production preincubated for 1 hr followed by LPS stimulation measured after 18 hrs by Griess assay Antiinflammatory activity in mouse RAW264.7 cells assessed as reduction in LPS-induced NO production preincubated for 1 hr followed by LPS stimulation measured after 18 hrs by Griess assay	[PMID: 29338260]
RAW264.7	IC₅₀	0.2 μM Compound: MG132	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-stimulated iNOS activity preincubated with compound for 24 hrs followed by LPS stimulation for 2 hrs and measured 2 hrs after NADPH addition by fluorescence based assay Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-stimulated iNOS activity preincubated with compound for 24 hrs followed by LPS stimulation for 2 hrs and measured 2 hrs after NADPH addition by fluorescence based assay	[PMID: 33454546]
RAW264.7	IC₅₀	0.2 μM Compound: MG132	Inhibition of NO production in LPS-stimulated mouse RAW264.7 cells preincubated with compound for 24 hrs followed by LPS stimulation and measured after 2 hrs by Griess reagent-based assay Inhibition of NO production in LPS-stimulated mouse RAW264.7 cells preincubated with compound for 24 hrs followed by LPS stimulation and measured after 2 hrs by Griess reagent-based assay	[PMID: 33454546]
RAW264.7	IC₅₀	0.35 μM Compound: MG-132	Inhibition of LPS-induced NO production in mouse RAW264.7 cells after 18 hrs Inhibition of LPS-induced NO production in mouse RAW264.7 cells after 18 hrs	[PMID: 21044847]
RAW264.7	IC₅₀	0.35 μM Compound: MG-132	Inhibition of NO production in Interferon gamma-stimulated mouse RAW264.7 cells after 18 hrs Inhibition of NO production in Interferon gamma-stimulated mouse RAW264.7 cells after 18 hrs	[PMID: 21044847]
RAW264.7	IC₅₀	0.439 μM Compound: MG-132	Antiinflammatory against mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production Antiinflammatory against mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production	[PMID: 21561060]
RAW264.7	IC₅₀	0.63 μM Compound: MG132	Toxicity against mouse RAW264.7 cells by XTT assay Toxicity against mouse RAW264.7 cells by XTT assay	[PMID: 22858297]
RAW264.7	IC₅₀	2.6 μM Compound: MG132	Anti-inflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production pretreated with compound for 2 hrs followed by LPS stimulation for 12 hrs by Griess reagent based analysis Anti-inflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production pretreated with compound for 2 hrs followed by LPS stimulation for 12 hrs by Griess reagent based analysis	[PMID: 36607819]
SW480	IC₅₀	29.5 μM Compound: MG132	Inhibition of NFkappaB transcription in human SW480 cells at by luciferase reporter gene assay Inhibition of NFkappaB transcription in human SW480 cells at by luciferase reporter gene assay	[PMID: 26841168]

In Vitro

MG-132 (Z-Leu-Leu-Leu-al) initiates neurite outgrowth in PC12 cells at a low concentration (30 nM) and is a very strong inhibitor of 20S proteasome^[3].
MG-132 (10 μM; 1 hour) reverses the effects of TNF- α on I κ B degradation and NF-κ B activation in A549 cells^[4].
MG-132 (0.75-5 μM; 24 hours) potently induces p53-dependent apoptosis in KIM-2 cells by 26S proteasome inhibition^[5].
MG-132 (10-40 μM; 24 hours) significantly reduces the viability of C6 glioma cells in both time- and concentration-dependent manners and shows the IC₅₀ of 18.5 μM at 24 hours^[6].
MG-132 (18.5 μM; 24 hours) induces down-regulation of anti-apoptotic proteins Bcl-2 and XIAP and up-regulates expression of pro-apoptotic protein Bax and caspase-3^[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[3]

Cell Line:	C6 glioma cells
Concentration:	10, 20, 30, 40 μM
Incubation Time:	24 hours
Result:	Significantly reduced the viability of C6 glioma cells beginning at 6 h in both time- and concentration-dependent manners and showed the IC₅₀ of 18.5 μM at 24 hours.

Western Blot Analysis^[3]

Cell Line:	A549 cells
Concentration:	10 μM
Incubation Time:	1 hour
Result:	Reversed the effects of TNF-α on IκB degradation and resulted in a reversal of TNF-α-induced NF-κB activation.

In Vivo

MG132 (10 mg/kg; i.p.; daily for 25 days starting 5 days after EC9706 cells injection) significantly inhibits tumor growth of the EC9706 xenograft without causing toxicity to mice^[7].
MG-132 (1 mg/kg; i.v.; twice a week for 4 weeks) shows potent tumor inhibitory effect against mice bearing HeLa tumors^[8].
MG-132 (1-10 μg/kg/24 hours; subcutaneously implanted osmotic pumps; for 8 days) greatly increases the expression levels of β-dystroglycan, α-dystroglycan, α-sarcoglycan, and dystrophin in skeletal muscle lysates in mice (six-month-old male C57BL/10ScSn DMD mdx mice)^[9].

Note:
Please do not refer to only one article to determine the experimental conditions. It is recommended to determine the optimal experimental conditions (animal strain, age, dosage, frequency and cycle, detection time and indicators, etc.) through preliminary experiments before the formal experiment.

MG-132, characterized by a short plasma half-life and poor blood-brain barrier permeability, is administered via stereotactic intranigral injection (0.4 μg) to achieve sustained local proteasome inhibition, successfully inducing Parkinson's disease-like pathology in the substantia nigra^[10].

Induction of Parkinson’s disease^[10]

Background

MG-132 induces Parkinson's disease-like pathology by inhibiting the ubiquitin-proteasome system (UPS), leading to proteolytic stress, apoptosis of dopaminergic neurons, and a consequent depletion of striatal dopamine^[10].

Specific Modeling Methods

Mice: C57BL/6 black mice
Administration: MG-132 (0.4 μg in 4 μL) • stereotaxically injected into the substantia nigra at the target site (Bregma AP, 3.2 mm, ML, 2.0 mm, DV, 4.7 mm) in the right side

Note

(1) MG-132 is dissolved at a concentration of 0.1 μg/μL in a vehicle of 1% DMSO in PBS.
(2) Injection should be extremely slow (e.g., 0.5 μL/min), and the needle should be left in place for several minutes after injection to prevent fluid reflux and mechanical damage that could affect model specificity.
(3) The control side must use the same solvent as the drug solution (1% DMSO in PBS) to eliminate the influence of the solvent itself.

Modeling Indicators

Molecular changes: Striatal dopamine and DOPAC depletion
Histology analysis: Nigral tyrosine hydroxylase-positive (TH+) neurons loss

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	5- to 6-weeks old female athymic nude mice (EC9706 xenograft)^[7]
Dosage:	10 mg/kg
Administration:	I.p.; daily for 25 days starting 5 days after EC9706 cells injection
Result:	Significantly inhibited tumor growth of the EC9706 xenograft without causing toxicity to the mice.

Animal Model:	Five-week-old female C.B-17/lcr-scid/scidJcl mice (bearing HeLa cells)^[8]
Dosage:	1 mg/kg
Administration:	Intravenous injection; twice a week for 4 weeks
Result:	The growth inhibition rates in HeLa tumors was 49% compared to the control.

Masse moléculaire

475.62

Formule

C₂₆H₄₁N₃O₅

CAS No.

133407-82-6

Appearance

Solid

Color

White to yellow

SMILES

O=C(OCC1=CC=CC=C1)N[C@H](C(N[C@@H](CC(C)C)C(N[C@H](C(19)=O)CC(C)C)=O)=O)CC(C)C

Livraison

Room temperature in continental US; may vary elsewhere.

Stockage

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvant et solubilité

In Vitro:

DMSO : ≥ 50 mg/mL (105.13 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.1025 mL	10.5126 mL	21.0252 mL
5 mM	0.4205 mL	2.1025 mL	4.2050 mL
10 mM	0.2103 mL	1.0513 mL	2.1025 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 1.67 mg/mL (3.51 mM); Clear solution

This protocol yields a clear solution of ≥ 1.67 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (16.7 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 1.67 mg/mL (3.51 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 1.67 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (16.7 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 1.67 mg/mL (3.51 mM); Clear solution

This protocol yields a clear solution of ≥ 1.67 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (16.7 mg/mL) to 900 μL Corn oil, and mix evenly.

Pureté et documentation

Purity: 99.97%

Fiche technique (285 KB) SDS (393 KB)

COA (246 KB) HNMR (280 KB) RP-HPLC (215 KB) MS (69 KB) Elemental Analysis Report (104 KB)

Instruction de manipulation (2659 KB)

Références

[1]. Harhouri K, et al. MG132-induced progerin clearance is mediated by autophagy activation and splicing regulation. EMBO Mol Med. 2017 Sep;9(9):1294-1313. [Content Brief]

[2]. Fan WH, et al. Proteasome inhibitor MG-132 induces C6 glioma cell apoptosis via oxidative stress. Acta Pharmacol Sin. 2011 May;32(5):619-25. [Content Brief]

[3]. Tsubuki S, et al. Differential inhibition of calpain and proteasome activities by peptidyl aldehydes of di-leucine and tri-leucine. J Biochem. 1996 Mar;119(3):572-6. [Content Brief]

[4]. Fiedler MA, et al. Inhibition of TNF-alpha-induced NF-kappaB activation and IL-8 release in A549 cells with the proteasome inhibitor MG-132. Am J Respir Cell Mol Biol. 1998 Aug;19(2):259-68. [Content Brief]

[5]. MacLaren AP, et al. p53-dependent apoptosis induced by proteasome inhibition in mammary epithelial cells. Cell Death Differ. 2001 Mar;8(3):210-8. [Content Brief]

[6]. Han YH, et al. The effect of MG132, a proteasome inhibitor on HeLa cells in relation to cell growth, reactive oxygen species and GSH. Oncol Rep. 2009 Jul;22(1):215-21. [Content Brief]

[7]. Dang L, et al. Proteasome inhibitor MG132 inhibits the proliferation and promotes the cisplatin-inducedapoptosis of human esophageal squamous cell carcinoma cells. Int J Mol Med. 2014 May;33(5):1083-8. [Content Brief]

[8]. Matsumoto Y, et al. Enhanced efficacy against cervical carcinomas through polymeric micelles physically incorporating theproteasome inhibitor MG132. Cancer Sci. 2016 Jun;107(6):773-81. [Content Brief]

[9]. Bonuccelli G, et al. Proteasome inhibitor (MG-132) treatment of mdx mice rescues the expression and membrane localization of dystrophin and dystrophin-associated proteins. Am J Pathol. 2003 Oct;163(4):1663-75. [Content Brief]

[10]. Sun F, et al. Proteasome inhibitor MG-132 induces dopaminergic degeneration in cell culture and animal models. Neurotoxicology. 2006 Sep;27(5):807-15. [Content Brief]

Vous serez peut-être également intéressé par les produits suivants :

Référence

Description

Cond.

Prix HT

AAH-CYT-5-8

Human Cytokine Array C5

8SampleKit

AAH-CYT-5-2

Human Cytokine Array C5

2SampleKit

MG-132 [133407-82-6]

Référence HY-13259-5mg

Marque : MedChemExpress

MG-132 Related Antibodies

Vous serez peut-être également intéressé par les produits suivants :